By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ipsen 

39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609


SEARCH JOBS


Industry
Pharmaceutical






Company News
Dominique Laymand Is Appointed As Ipsen (IPN.PA)’s Senior Vice President, Chief Ethics And Compliance Officer 3/2/2015 10:30:47 AM
Ipsen (IPN.PA) Announces Third Resupply Of Increlex (Mecasermin [rDNA Origin] Injection) In The U.S. In 2015 3/2/2015 10:20:24 AM
Ipsen (IPN.PA) Enters Into Option Agreement To Acquire Canbex Therapeutics 2/24/2015 10:29:55 AM
Ipsen (IPN.PA): Sales In The Fourth Quarter And Full Year 2014 2/3/2015 12:58:14 PM
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 2/3/2015 11:20:23 AM
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 1/26/2015 10:11:48 AM
Ipsen (IPN.PA) To Present Further Data On Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (Lanreotide), At Gastrointestinal Cancers Symposium 1/13/2015 7:33:08 AM
Ipsen (IPN.PA) Announces FDA Approval Of Somatuline® Depot® (Lanreotide) Injection For The Treatment Of Gastroenteropancreatic Neuroendocrine Tumors 12/17/2014 11:04:33 AM
François Garnier Appointed Executive Vice President, General Counsel Of Ipsen (IPN.PA) 12/16/2014 10:21:10 AM
Ipsen (IPN.PA) Announces That The International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen 12/12/2014 10:08:33 AM
12345678910...
//-->